Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
1995-06-07
2001-07-31
Woodward, Michael P. (Department: 1631)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C530S350000, C530S389400, C424S189100, C424S227100
Reexamination Certificate
active
06268122
ABSTRACT:
TECHNICAL FIELD OF INVENTION
This invention relates to recombinant DNA molecules and their method of production. This invention relates more particularly to recombinant DNA molecules expressed in appropriate host organisms. The recombinant DNA molecules disclosed herein are characterized by the DNA that codes for polypeptides with the specificity of hepatitis B viral antigens. As will be appreciated from the disclosure to follow, the recombinant DNA molecules may be used in the detection of hepatitis B virus in man and the stimulation of antibodies in humans against this virus.
BACKGROUND ART
The virus that causes hepatitis B or serum hepatitis appears to infect only man. Hepatitis B virus (“HBV”) infection in humans is widespread. In the United Kingdom, United States, and Western Europe, approximately 0.1% of all blood donors are chronic carriers of HBV. While the death rate due to viral hepatitis is not high (in 1975 in the United Kingdom it was 3 per million), there are indications that as many as 5% of the population in the United Kingdom and 15% of the population in the United States have been infected. In many African and Asian countries, up to twenty percent of the population are chronic carriers of HBV, and over fifty percent of all adults in those countries have been or are infected with HBV.
The hepatitis infection is transmitted by three general mechanisms: (1) by parenteral inoculation of infected blood or body fluids, either in large amounts as in blood transfusions or in minute amounts as through an accidental skinprick; (2) by close family or sexual contact; and (3) by some mothers, who infected during pregnancy, transmit the virus to their new-born children. Under natural conditions, HBV is not highly contagious. Transmission by inhalation occurs rarely, if ever.
Most HBV infections are subclinical. The clinical illness usually lasts three to six weeks and ranges in severity from mild to acute fulminating hepatitis followed by cirrhosis or death. Recovery from clinical and subclinical HBV infections is usually complete. However, serious long term consequences result in some cases: (1) approximately five percent of acute infections lead to chronic carriage of hepatitis B virus antigen with its continuing potential for infectivity to others and ongoing liver damage; and (2) it is likely that past infection with HBV may be wholly or partly responsible for the initiation of a significant proportion of HBV-seronegative cases of chronic active hepatitis, cirrhosis and primary liver carcinoma.
Recent advances in molecular biology have made it possible to introduce the DNA coding for specific non-bacterial eukaryotic proteins into bacterial cells. In general, with DNA other than that prepared via chemical synthesis, the construction of the recombinant DNA molecules comprises the steps of producing a single-stranded DNA copy (cDNA) of a purified messenger (mRNA) template for the desired protein; converting the cDNA to double-stranded DNA; linking the DNA to an appropriate site in an appropriate cloning vehicle and transforming an appropriate host with that recombinant DNA molecule. Such transformation permits the host to produce the desired protein. In addition, at least in the case of ovalbumin DNA, it is known that appropriate fusion of the particular DNA to a strong bacterial promoter or expression control sequence produces larger amounts of the desired ovalbumin protein, i.e., about 0.5 to 1% of the total protein mass of an
E. coli
cell (O. Mercereau-Puijalon et al., “Synthesis Of An Ovalbumin-Like Protein By
Escherichia coli
K12 Harboring A Recombinant Plasmid”,
Nature,
275, pp. 505-510 (1978) and T. H. Fraser and B. J. Bruce, “Chicken Ovalbumin Is Synthesized And Secreted By
Escherichia coli”, Proc. Natl. Acad. Sci. USA,
75, pp. 5936-5940 (1978)).
Several non-bacterial proteins and genes have been synthesized using recombinant DNA technology. These include a protein displaying rat proinsulin antigenic determinants (L. Villa-Komaroff et al., “A Bacterial Clone Synthesizing Proinsulin”,
Proc. Natl. Acad. Sci. USA,
75, pp. 3727-3731 (1978)), rat growth hormone (P. H. Seeburg et al., “Synthesis Of Growth Hormone By Bacteria”,
Nature,
276, pp. 795-798 (1978)), mouse dihydrofolate reductase (A. C. Y. Chang et al., “Phenotypic Expression in
E. coli
Of A DNA Sequence Coding For Mouse Dihydrofolate Reductase”,
Nature,
275, pp. 617-624 (1978)), somatostatin (K. Itakura et al., “Expression In
Escherichia coli
Of A Chemically Synthesized Gene For The Hormone Somatostatin”,
Science,
198, 1056-1063 (1977), United Kingdom patent specifications 2,007,675A, 2,007,676A and 2,008,123A and cognate applications in other countries), and the A and B polypeptide chains of human insulin (D. V. Goeddel et al., “Expression In
Escherichia coli
Of Chemically Synthesized Genes For Human Insulin”,
Proc. Natl. Acad. Sci. USA,
76, pp. 106-110 (1979) and the United Kingdom and related patent specifications, supra).
None of the foregoing, however, is directed, as is this invention, toward the recombinant DNA synthesis of viral proteins such as hepatitis B virus antigens.
It is known that HBV infections cause development of antibodies to the antigens of the virus. These antibodies are the body's defense Mechanism to the HBV infection. The development of such antibodies prior to exposure or rapidly in the case of potential exposure should substantially reduce and combat virus growth and spread in the patient.
A problem however in the artificially stimulated development of antibodies to the antigens of hepatitis B virus is the limited host range of the virus. For example, although highly infectious to man, experimental infection with hepatitis B virus has been achieved in only a few additional primates. And, the virus has not been propagated in tissue culture. This limited host range and inability to infect tissue culture cells has severely hampered both the characterization of the virus and the pathology of its infection and the development of rapid detection means and effective means of infection control and prevention.
While there have been some attempts to employ authentic HBV viral antigens, isolated from victims of the HBV infection, for the development of antibodies and detection of infection, these treatments are not generally available because of the limited supply of the active species. Furthermore, the use of human sources for these antigens is disfavored because. of the well recognized contamination problems in using human isolates.
DISCLOSURE OF THE INVENTION
The present invention solves the problems referred to by providing in accordance with the invention a recombinant DNA molecule characterized by a structural gene coding for a polypeptide displaying HBV antigenicity.
By virtue of our invention, it is possible to obtain HBV antigens and genes in substantial and uncontaminated quantities for vaccine preparations and for use in detection of the viral infection and determination of its pathology and molecular biology. Such supplies have not hitherto been available, because of the narrow host range of the virus and its inability to be grown in tissue culture.
As will be appreciated from the disclosure to follow, the recombinant DNA molecule of the invention is capable of producing, in an appropriate host, at least one viral polypeptide displaying HBV antigenicity and the structural genes that code therefor. These recombinant DNA molecules and hosts may be utilized to prepare polypeptides displaying HBV antigenicity and structural genes coding for these polypeptides. These products may also be identified and characterized and are useful either as produced in the host or after appropriate derivatization or modification in compositions and methods for improving production of these products themselves and for detecting HBV infection, tracing its pathology and stimulating the production of HBV antibodies in humans.
In accordance with the invention we also provide a process for producing a recombinant DNA molecule, characterized by linking a DNA sequence prepared fr
Biogen Inc.
Fish & Neave
Haley Jr. James F.
Pierri Margaret A.
Woodward Michael P.
LandOfFree
Recombinant DNA molecules and their method of production does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant DNA molecules and their method of production, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant DNA molecules and their method of production will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2479127